These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 31921375)

  • 1. Low Body Mass Index Is an Independent Prognostic Factor in Patients With Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
    Minami S; Ihara S; Nishimatsu K; Komuta K
    World J Oncol; 2019 Dec; 10(6):187-198. PubMed ID: 31921375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcopenia and Visceral Adiposity Did Not Affect Efficacy of Immune-Checkpoint Inhibitor Monotherapy for Pretreated Patients With Advanced Non-Small Cell Lung Cancer.
    Minami S; Ihara S; Tanaka T; Komuta K
    World J Oncol; 2020 Feb; 11(1):9-22. PubMed ID: 32095185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcopenia and Visceral Adiposity Are Not Independent Prognostic Markers for Extensive Disease of Small-Cell Lung Cancer: A Single-Centered Retrospective Cohort Study.
    Minami S; Ihara S; Komuta K
    World J Oncol; 2020 Aug; 11(4):139-149. PubMed ID: 32849954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment Lung Immune Prognostic Index Is a Prognostic Marker of Chemotherapy and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
    Minami S; Ihara S; Komuta K
    World J Oncol; 2019 Feb; 10(1):35-45. PubMed ID: 30834050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gustave Roussy Immune Score Is a Prognostic Factor for Chemotherapy-Naive Pulmonary Adenocarcinoma With Wild-Type Epidermal Growth Factor Receptor.
    Minami S; Ihara S; Komuta K
    World J Oncol; 2019 Feb; 10(1):55-61. PubMed ID: 30834052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of sarcopenia in patients with lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors.
    Lyu J; Yang N; Xiao L; Nie X; Xiong J; Liu Y; Zhang M; Zhang H; Tang C; Pan S; Liang L; Bai H; Li C; Kuang H; Li T
    Front Nutr; 2023; 10():1113875. PubMed ID: 36969820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival of Advanced Non-Small Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor.
    Minami S; Ogata Y; Ihara S; Yamamoto S; Komuta K
    World J Oncol; 2017 Dec; 8(6):180-187. PubMed ID: 29317963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer.
    Su PL; Chen CW; Wu YL; Lin CC; Su WC
    Thorac Cancer; 2021 Feb; 12(3):287-296. PubMed ID: 33336895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes in patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer in South Western Sydney Local Health District.
    Ding PN; Roberts TL; Chua W; Becker TM; Descallar J; Yip PY; Bray V
    Intern Med J; 2017 Dec; 47(12):1405-1411. PubMed ID: 28742280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival analysis of patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment of Yunnan in southwestern China: a real-world study.
    Lin Y; Chen L; Li R; Liu X; Li Q; Cai J; Du Y; Zhao G; Wang X; Shen Z; Liao Y; Chen Y; Xie L; Zhou Y; Huang Y
    Front Oncol; 2023; 13():1156647. PubMed ID: 37881485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
    Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
    Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy.
    Yun NK; Rouhani SJ; Bestvina CM; Ritz EM; Gilmore BA; Tarhoni I; Borgia JA; Batus M; Bonomi PD; Fidler MJ
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis.
    Tsai JS; Su PL; Yang SC; Chang CC; Lin CY; Yen YT; Tseng YL; Lai WW; Lin CC; Su WC
    J Formos Med Assoc; 2021 Sep; 120(9):1729-1739. PubMed ID: 33865672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment neutrophil-to-lymphocyte ratio is a predictive biomarker for EGFR TKI-treated patients with advanced EGFR-mutant Non-small cell lung cancer.
    Xu C; Yao X; Li T; Wang J; An B; Wang J; Sui X; Leung EL; Wu Q
    Transl Cancer Res; 2020 Apr; 9(4):2875-2883. PubMed ID: 35117644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations.
    Park S; Park S; Lee SH; Suh B; Keam B; Kim TM; Kim DW; Kim YW; Heo DS
    Korean J Intern Med; 2016 Nov; 31(6):1140-1149. PubMed ID: 27017943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio for
    Gan Y; Ren J; Xian J; Yu H; Jin J; Li D; Li W
    Int J Gen Med; 2022; 15():3405-3416. PubMed ID: 35378914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment.
    Kasahara N; Imai H; Naruse I; Tsukagoshi Y; Kotake M; Sunaga N; Kaira K; Maeno T; Asao T; Hisada T
    Thorac Cancer; 2020 Aug; 11(8):2188-2195. PubMed ID: 32495520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC.
    Zhang Y; Zeng L; Zhang X; Li Y; Liu L; Xu Q; Yang H; Jiang W; Lizaso A; Qiu L; Hou T; Liu J; Peng L; Yang N
    BMC Med; 2021 Oct; 19(1):245. PubMed ID: 34663309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.